Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- Quality Adjusted Life Years
- QALY
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in this website by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 3 | 4 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 2 | 4 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 4 | 4 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 5 | 5 |
| 2011 | 1 | 4 | 5 |
| 2012 | 4 | 6 | 10 |
| 2013 | 2 | 7 | 9 |
| 2014 | 2 | 7 | 9 |
| 2015 | 2 | 12 | 14 |
| 2016 | 0 | 5 | 5 |
| 2017 | 3 | 10 | 13 |
| 2018 | 4 | 7 | 11 |
| 2019 | 0 | 4 | 4 |
| 2020 | 3 | 10 | 13 |
| 2021 | 1 | 8 | 9 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 4 | 4 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions. Ann Am Thorac Soc. 2024 Dec; 21(12):1759-1769.
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
-
The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2481-2489.e1.
-
Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression. Transl Psychiatry. 2024 Jun 07; 14(1):243.
-
Is Blepharoplasty Cost-effective? Utility Analysis of Dermatochalasis and Cost-effectiveness Analysis of Upper Eyelid Blepharoplasty. Ophthalmic Plast Reconstr Surg. 2024 Sep-Oct 01; 40(5):552-559.
-
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.
-
Cardiovascular disease burden in the Middle East and North Africa region. Curr Probl Cardiol. 2024 Mar; 49(3):102341.
-
Hearing Loss Prevalence, Years Lived With Disability, and Hearing Aid Use in the United States From 1990 to 2019: Findings From the Global Burden of Disease Study. Ear Hear. 2024 Jan-Feb 01; 45(1):257-267.
-
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2023 08; 41(8):857-867.
-
Cost-utility analysis of a multispecialty interprofessional team dementia care model in Ontario, Canada. BMJ Open. 2023 04 19; 13(4):e064882.